Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01277549 · ClinicalTrials.gov registry record
Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors
A clinical trial, sponsored by Terumo BCT.
- Completed
- Registry status
- 71
- Enrollment target
NCT01277549 is a clinical trial that has completed, run by Terumo BCT. The registered enrollment target is 71 participants.
The verdict
NCT01277549 has completed, sponsored by Terumo BCT.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
The purpose of this protocol is to characterize the performance of CaridianBCT's Spectra Optia Apheresis System, when used to collect mononuclear cells (MNCs) and cluster of differentiation 34 (CD34) positive cells from healthy nonmobilized blood donors and healthy G-CSF (granulocyte colony stimulating factor) mobilized blood donors, respectively.
Interventions
- DEVICE Mononuclear cell collection.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01277549
The ClinicalTrials.gov registry entry for NCT01277549 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Terumo BCT, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mononuclear cell collection. is the first listed.
NCT01277549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01277549 about?
NCT01277549 is a clinical study titled "Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors". The purpose of this protocol is to characterize the performance of CaridianBCT's Spectra Optia Apheresis System, when used to collect mononuclear cells (MNCs) and cluster of differentiation 34 (CD34) positive cells from healthy nonmobilized blood donors and healthy G-CSF (granulocyte colony stimulat...
What is the current status of trial NCT01277549?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2011-01. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01277549?
The interventions under investigation include: Mononuclear cell collection. (DEVICE).
Who is sponsoring clinical trial NCT01277549?
This trial is sponsored by Terumo BCT, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.